Clinical trial
A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical…
NCT00264732 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00264732 |
|---|---|
| Title | A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix |
| Official title | A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Uterine Cervical Dysplasia |
| Intervention type | Drug, Other |
| Interventions | Amolimogene, Placebo |
| Enrollment | 251 |
| Start date | Jul 1, 2005 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Dec 13, 2005 |
| Last update posted | May 29, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: